Reducing vaccine prices and securing stable supply are critical to increasing access to the vaccines that can prevent NCDs.
Hepatitis B vaccine shows what can be achieved. With increased demand from developing countries and growing competition among vaccine manufacturers, the cost of the hepB vaccine fell 68% from 2000-2010.
The high price of HPV vaccines is currently a barrier to their introduction in developing countries. GAVI is working with manufacturers to lower the cost to an affordable and sustainable level.
